GDF15 and Cachexia: In a phase 2 trial, visugromab, a humanized monoclonal antibody neutralizing GDF15, combined with nivolumab, demonstrated increased and durable responses in several heavily pretreated solid tumor cohorts and appeared to improve weight gain in patients with manifest cachexia [157].